s	ubstitute for form 1449A/PTO		COMPLETE IF KNOWN		
]	INFORMATION	N DISCLOSURE	Application Number	10/520,925	
	TATEMENT D	Y APPLICANT'S	Filing Date	September 26, 2005	
	IAIEMENI D	/ 3\	First Named Inventor	Olsen, David B. et al.	
	(JUL 3 1 2007	Group Art Unit	1624	
	(use as many shee	ets as recessary)	Examiner Name	Berch, Mark L.	
Sheet	. 1	of MADE	Attorney Docket Number	21194P	

	U.S. PATENT DOCUMENTS							
Examiner Initials*	Cite No.	U.S. Patent Docur Number	nent Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY			
	_							
				•				
				•				
	-							

			FOREI	GN PATENT	DOCUMENTS	
Examiner Initials*	Cite No.	Office	Foreign Patent Documen Number	t Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY
/MB/		wo	2004/072090	A1	Merck & Co., Inc.	08/26/2004
/MB/		wo	2004/009020	A2	Merck & Co., Inc.; ISIS Pharmaceuticals, Inc.	01/29/2004
/MB/		wo	2004/007512	A2	Merck & Co., Inc.; ISIS Pharmaceuticals, Inc.	01/22/2004
/MB/		wo	2004/000858	A2	Merck & Co., Inc.; ISIS Pharmaceuticals, Inc.	12/31/2003
/MB/		wo	03/105770	A2	Merck & Co., Inc.; ISIS Pharmaceuticals, Inc.	12/24/2003
/MB/		wo	03/068244	A1	Merck & Co., Inc.; ISIS Pharmaceuticals, Inc.	08/21/2003

Examiner Signature Date Considered

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Su	Substitute for form 1449B/PTO		COMPLETE IF KNOWN			
	NFORMATION I	DISCLOSU	RE	Application Number	10/520,925	
C'	STATEMENT BY APPLICANT			Filing Date	September 26, 2005	
3				First Named Inventor	Olsen, David B. et al.	
	6			Group Art Unit	1624	
	(use as many sheets as necessary)			Examiner Name	Berch, Mark L.	
Sheet	2	of 2	2	Attorney Docket Number	21194P	

	NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.	Include name of the author, title, date, page(s), volume-issue number(s) and place of publication.					
/MB/		Murai, Y. et al. "A Synthesis and an X-Ray Analysis of 2'-C-, 3'-C-, and 5'-C-Methylsangivamycins", Heterocycles, 1992, Vol. 33, pp. 391-404					
/MB/		Iimori, T. et al. "A study on conformationally restricted sangivamycins and their inhibitory abilities of protien kinases", Oxford University Press, 1992, pp. 169-170					
7							
		-					
		•					

Evenines			
Examiner Signature	/Mark Berch/ (08/24/2007)	Date	
J.B.iata. 6	the first and the second secon	Considered	

^{*}Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

SEND TO: Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450. Computer generated form * IDS Form* (IDS Folder), Merck & Co., Inc., 06/28/2007